Related News Articles

12/16/2024

Dealing with companies, customer service can take valuable time. Let your favorite AI bot come to the rescue.

12/04/2024

Study notes critical gaps in care and services that must be addressed to meet the growing demands of the aging population in the U.S. 

12/03/2024

After multiple undetected falls, the son decided to take his mother home. 

11/27/2024

Every year, falls among older Americans result in about 3.6 million ER visits and 1.2 million hospital stays, costing roughly $80 billion. 

10/16/2024

About 74% of middle-aged and senior Americans would have very little to no trust in health info generated by AI.

You are here

SiPhox Health Introduces World's First Lab-Quality Home Blood Testing Platform at CES

LAS VEGAS, Jan. 5, 2023 /PRNewswire/ -- Backed by Khosla Ventures and Ycombinator, SiPhox Health is the first healthcare company to leverage silicon photonic chips to make diagnostics 100x faster, smaller, and less expensive – without sacrificing quality.

SiPhox Home consumer blood testing platform. This device is available for investigational use only.

The SiPhox Home, currently available for investigational use only, is designed to measure a range of immunoassays for key biomarkers of inflammation, metabolism, hormonal, and heart health in a single sample. The platform requires less than a drop of blood, delivers results in under 5 minutes and has been externally validated against traditional central lab methods.

"Silicon Photonics has revolutionized the way internet data is transmitted, creating the modern world of Zoom and constant connectivity," says SiPhox CoFounder Diedrik Vermeulen, "SiPhox has applied this powerful semiconductor platform to enable testing that is 100x smaller, faster, and cheaper than anything out there - without sacrificing any quality or accuracy."

SiPhox will be conducting live testing and demonstrations at CES (booth #61314) Las Vegas on January 5th - 7th.

Note that the SiPhox Home has not been evaluated by the FDA and is only available for investigational use.

For press inquiries, please contact Lauren Weiniger at 351488@email4pr.com.

Thursday, January 5, 2023

Categories

login account